Chunhong Hu

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4K citations

Medicine, Pathology, Bronchial Neoplasm +8

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 387 citations

Oncology, Metronomic Therapy, Nasopharyngeal Cancer +7

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · Journal of Clinical Oncology · 2015 · 381 citations · Full text

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Jie Wang, Shun Lü, Xinmin Yu et al. · JAMA Oncology · 2021 · 381 citations · Full text